(NASDAQ: AMLX) Amylyx Pharmaceuticals's forecast annual revenue growth rate of -40.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Amylyx Pharmaceuticals's revenue in 2025 is $87,371,000.On average, 1 Wall Street analysts forecast AMLX's revenue for 2026 to be $57,591,604, with the lowest AMLX revenue forecast at $57,591,604, and the highest AMLX revenue forecast at $57,591,604. On average, 2 Wall Street analysts forecast AMLX's revenue for 2027 to be $1,668,384,472, with the lowest AMLX revenue forecast at $1,121,707,245, and the highest AMLX revenue forecast at $2,215,061,700.
In 2028, AMLX is forecast to generate $4,174,505,280 in revenue, with the lowest revenue forecast at $3,918,887,160 and the highest revenue forecast at $4,430,123,400.